Krystal Biotech Develops Gene Therapy for Rare Skin Disorder

Suma Krishnan, founder and president of Krystal Biotech, presented details of a gene therapy approach for epidermolysis bullosa during a joint America 250 and Forbes America Innovates stage appearance. The rare disease prevents full skin formation in children at birth. Krishnan holds the additional title of Forbes 250 America’s Greatest Living Innovators honoree.

Krishnan described how the therapy is designed to address the underlying genetic cause of the condition. The presentation occurred as part of the America 250 x Forbes America Innovates program. No further details on clinical trial results, regulatory status, or patient outcomes were provided in the remarks.